November 30, 2011
A Pennsylvania federal court on Tuesday dismissed a False Claims Act suit accusing Genentech Inc. of fraudulently marketing its non-Hodgkin lymphoma drug Rituxan, after the California-based biotechnology company settled the suit for $20 million.